2019
Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma
Mohan D, Lerario A, Else T, Mukherjee B, Almeida M, Vinco M, Rege J, Mariani B, Zerbini M, Mendonca B, Latronico A, Marie S, Rainey W, Giordano T, Fragoso M, Hammer G. Targeted Assessment of G0S2 Methylation Identifies a Rapidly Recurrent, Routinely Fatal Molecular Subtype of Adrenocortical Carcinoma. Clinical Cancer Research 2019, 25: 3276-3288. PMID: 30770352, PMCID: PMC7117545, DOI: 10.1158/1078-0432.ccr-18-2693.Peer-Reviewed Original ResearchConceptsUpregulation of cell cycleDNA damage response programsAdrenocortical carcinomaTargeted bisulfite sequencingCancer Genome Atlas projectBisulfite sequencingCpG island hypermethylation phenotypeHypermethylation phenotypeAggressive adrenocortical carcinomasCell cycleMolecular markersBiological processesHypermethylationMolecular diagnosticsShorter disease-freeCancers of patientsBiomarker methylationAtlas projectEfficacious adjuvant therapyLocoregional diseaseOverall survivalAdjuvant therapyAdrenocortical tumorsDismal outcomeSilencing
2016
Decreased Anti-Tumor Cytotoxic Immunity among Microsatellite-Stable Colon Cancers from African Americans
Basa R, Davies V, Li X, Murali B, Shah J, Yang B, Li S, Khan M, Tian M, Tejada R, Hassan A, Washington A, Mukherjee B, Carethers J, McGuire K. Decreased Anti-Tumor Cytotoxic Immunity among Microsatellite-Stable Colon Cancers from African Americans. PLOS ONE 2016, 11: e0156660. PMID: 27310868, PMCID: PMC4911070, DOI: 10.1371/journal.pone.0156660.Peer-Reviewed Original ResearchConceptsGranzyme B+ cellsColorectal cancerCytotoxic immunityB+ cellsAnti-tumor cytotoxic T lymphocytesColon cancerMicrosatellite-stable colon cancerCytotoxic T lymphocytesIL-17 expressionWilcoxon rank sum testProtection to patientsAfrican American colorectal cancerRank sum testTwo-sample Wilcoxon rank-sum testCD57+CD8+Invasive borderCytotoxic markersNo significant differenceT lymphocytesColon tumorsDescriptive summary statisticsImmune biomarkersTumor samplesImmune cytotoxicityMicrosatellite Alterations With Allelic Loss at 9p24.2 Signify Less-Aggressive Colorectal Cancer Metastasis
Koi M, Garcia M, Choi C, Kim H, Koike J, Hemmi H, Nagasaka T, Okugawa Y, Toiyama Y, Kitajima T, Imaoka H, Kusunoki M, Chen Y, Mukherjee B, Boland C, Carethers J. Microsatellite Alterations With Allelic Loss at 9p24.2 Signify Less-Aggressive Colorectal Cancer Metastasis. Gastroenterology 2016, 150: 944-955. PMID: 26752111, PMCID: PMC4808397, DOI: 10.1053/j.gastro.2015.12.032.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorChi-Square DistributionChromosome AberrationsChromosomes, Human, Pair 9Colorectal NeoplasmsDisease ProgressionDisease-Free SurvivalFemaleGenetic Predisposition to DiseaseHumansJapanKaplan-Meier EstimateLiver NeoplasmsLogistic ModelsLoss of HeterozygosityMaleMicrosatellite RepeatsMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPhenotypeProportional Hazards ModelsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Republic of KoreaRisk FactorsTime FactorsTreatment OutcomeConceptsPrimary colorectal tumorsLoss of heterozygosityLiver metastasesColorectal cancerColorectal tumorsElevated microsatellite alterationsMicrosatellite alterationsStage IICurative treatment of patientsStage III colorectal cancerOverall survival of patientsSurvival of patientsIII colorectal cancerTumor to liverColorectal cancer recurrenceTreatment of patientsMatched liver metastasesCancer cell nucleiMatched metastasesDisease recurrenceOverall survivalPrognostic factorsAllelic lossNo significant differenceCurative treatment
2013
Transcriptome Profiling Identifies HMGA2 as a Biomarker of Melanoma Progression and Prognosis
Raskin L, Fullen D, Giordano T, Thomas D, Frohm M, B. K, Ahn J, Mukherjee B, Johnson T, Gruber S. Transcriptome Profiling Identifies HMGA2 as a Biomarker of Melanoma Progression and Prognosis. Journal Of Investigative Dermatology 2013, 133: 2585-2592. PMID: 23633021, PMCID: PMC4267221, DOI: 10.1038/jid.2013.197.Peer-Reviewed Original ResearchConceptsAmerican Joint Committee on CancerOverall survivalTissue microarrayPrimary melanomaMelanoma pathogenesisMelanoma progressionAssociated with disease-free survivalAnalysis of tissue microarraysMetastases-free survivalDisease-free survivalHMGA2 overexpressionCox proportional hazards regression modelsLog-rank testPredictors of survivalProportional hazards regression modelsHazards regression modelsBRAF/NRAS mutationsPrimary tumorPrognostic featuresMelanoma metastasesClinicopathological characteristicsReal-time PCRGenetic alterationsAQUA analysisMelanoma development
2008
Adenoma-infiltrating Lymphocytes (AILs) are a Potential Marker of Hereditary Nonpolyposis Colorectal Cancer
Polydorides A, Mukherjee B, Gruber S, McKenna B, Appelman H, Greenson J. Adenoma-infiltrating Lymphocytes (AILs) are a Potential Marker of Hereditary Nonpolyposis Colorectal Cancer. The American Journal Of Surgical Pathology 2008, 32: 1661-1666. PMID: 18753941, PMCID: PMC3500084, DOI: 10.1097/pas.0b013e31816ffa80.Peer-Reviewed Original ResearchConceptsHereditary nonpolyposis colorectal cancer syndromeColorectal adenomasControl adenomasHereditary nonpolyposis colorectal cancer patientsColorectal cancer syndromePresence of high-grade dysplasiaTumor-infiltrating lymphocytesHigh-grade dysplasiaPresence of necrosisNumbers of mitotic figuresColorectal cancer patientsHost immune responseVillous componentCancer syndromesLack of dirty necrosisSerrated architectureMicrosatellite-unstable colorectal cancersPatient ageGeneral populationPoor differentiationDirty necrosisInexpensive markerHistological featuresColorectal cancerAdenomas